Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent Continue reading QIDP Antibiotics – 2015 Year-End Update
Looking at the molecular structure of ceftazidime (CTAZ) and aztreonam (ATM), the differences are clear, and so are the similarities: ATM does not have the cephem ring structure of CTAZ, only the 4-member beta-lactam ring. However, the side chains are identical in both CTAZ and ATM which explains the overlapping Continue reading Aztreonam PLUS Avibactam – A New Bright Star in the Night Sky
Roche’s current Phase 2 program is strangely ambiguous. RG-7929 has not made it into www.clinicaltrials.gov yet, only POL7080 is listed. An uncontrolled open label study in “patients with non-CF acute exacerbation of bronchiectasis due to P. aeruginosa requiring IV treatment” is enrolling. Well, good luck finding those patients! At best, Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 2)